UBS AG Increases Merck & Company, Inc. (NYSE:MRK) Price Target to $72.00

Merck & Company, Inc. (NYSE:MRK) had its price target boosted by equities research analysts at UBS AG from $70.00 to $72.00 in a note issued to investors on Monday, July 31st, 99wallstreet.com reports. The firm currently has a “buy” rating on the stock. UBS AG’s price objective would suggest a potential upside of 15.42% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. BidaskClub lowered shares of Merck & from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. BMO Capital Markets restated an “outperform” rating and set a $73.00 price target (down previously from $74.00) on shares of Merck & in a research note on Monday, July 24th. Zacks Investment Research lowered shares of Merck & from a “buy” rating to a “hold” rating in a research note on Thursday, May 25th. Jefferies Group LLC restated a “sell” rating and set a $51.00 price target on shares of Merck & in a research note on Wednesday, May 24th. Finally, Vetr lowered shares of Merck & from a “strong-buy” rating to a “buy” rating and set a $69.99 price objective for the company. in a research note on Wednesday, May 17th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $69.58.

Merck & (MRK) opened at 62.38 on Monday. The firm has a market capitalization of $170.13 billion, a price-to-earnings ratio of 33.77 and a beta of 0.80. The stock has a 50 day moving average price of $63.36 and a 200 day moving average price of $63.80. Merck & has a 1-year low of $58.29 and a 1-year high of $66.80.

Merck & (NYSE:MRK) last announced its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The business had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. During the same quarter last year, the firm earned $0.93 EPS. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. Analysts predict that Merck & will post $3.87 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “UBS AG Increases Merck & Company, Inc. (NYSE:MRK) Price Target to $72.00” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/12/merck-company-inc-nysemrk-pt-raised-to-72-00-at-ubs-ag-updated.html.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Veritable L.P. increased its position in shares of Merck & by 0.3% in the second quarter. Veritable L.P. now owns 193,589 shares of the company’s stock valued at $12,407,000 after buying an additional 498 shares in the last quarter. Waters Parkerson & CO. LLC increased its position in shares of Merck & by 0.7% in the second quarter. Waters Parkerson & CO. LLC now owns 276,854 shares of the company’s stock valued at $17,744,000 after buying an additional 1,872 shares in the last quarter. OxFORD Asset Management LLP increased its position in shares of Merck & by 960.3% in the second quarter. OxFORD Asset Management LLP now owns 155,271 shares of the company’s stock valued at $9,951,000 after buying an additional 140,627 shares in the last quarter. Epoch Investment Partners Inc. increased its position in shares of Merck & by 7.6% in the second quarter. Epoch Investment Partners Inc. now owns 2,882,095 shares of the company’s stock valued at $184,714,000 after buying an additional 202,612 shares in the last quarter. Finally, Virtu KCG Holdings LLC increased its position in shares of Merck & by 580.2% in the second quarter. Virtu KCG Holdings LLC now owns 122,769 shares of the company’s stock valued at $7,868,000 after buying an additional 104,719 shares in the last quarter. Hedge funds and other institutional investors own 73.73% of the company’s stock.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit